Compare
Bluejay Diagnostics, Inc. vs Glucotrack, Inc. vs Biotricity Inc. vs Aethlon Medical Inc
| Latest fiscal year | Bluejay Diagnostics, Inc. BJDX | Glucotrack, Inc. GCTKRevenue covers only part of its income (partial revenue) | Biotricity Inc. BTCY | Aethlon Medical Inc AEMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2026-03-31 |
| Revenue | n/a | n/a | $16.00M | n/a |
| Revenue growth (YoY) | n/a | n/a | +16.0% | n/a |
| Gross margin | n/a | n/a | 80.9% | n/a |
| Operating margin | n/a | n/a | 10.6% | n/a |
| Net margin | n/a | n/a | -15.0% | n/a |
| Net income | -$6.85M | -$19.39M | -$2.40M | -$7.15M |
| EPS (Diluted) | -$15.25 | $31.22 | -$0.12 | -$10.61 |
| Operating cash flow | -$6.05M | -$15.24M | -$719.0K | -$7.00M |
| Free cash flow | -$6.23M | -$15.34M | n/a | -$7.00M |
| Cash & equivalents | $5.16M | $7.38M | $149.8K | $5.03M |
| Total assets | $7.12M | $7.84M | $6.45M | $6.33M |
| Total liabilities | $1.14M | $5.01M | $39.41M | $1.45M |
| Shareholders' equity | $5.98M | $2.83M | -$34.68M | $4.89M |
| Return on year-end equity | -114.6% | -685.6% | n/a | -146.4% |
| Shares outstanding | 604.5K | 910.7K | 28.60M | 1.57M |
Revenue, most recent five fiscal years
| Fiscal year | Bluejay Diagnostics, Inc. | Glucotrack, Inc. | Biotricity Inc. | Aethlon Medical Inc |
|---|---|---|---|---|
| Latest | $249.0K Ended 2022-12-31 | n/a | $16.00M Ended 2026-03-31 | $0 Ended 2024-03-31 |
| 1 year earlier | n/a | n/a | $13.79M Ended 2025-03-31 | $574.2K Ended 2023-03-31 |
| 2 years earlier | n/a | n/a | $12.06M Ended 2024-03-31 | $294.2K Ended 2022-03-31 |
| 3 years earlier | n/a | n/a | $9.64M Ended 2023-03-31 | $659.1K Ended 2021-03-31 |
| 4 years earlier | n/a | n/a | $7.65M Ended 2022-03-31 | $650.2K Ended 2020-03-31 |